UK NEQAS
Blood Coagulation

3rd Floor, Pegasus House
463A Glossop Road
Sheffield S10 2QD
E-mail: neqas@coageqa.org.uk
Website: www.ukneqasbc.org

Sheffield Teaching Hospitals NHS
NHS Foundation Trust

Professor ID Walker (Director)
.
Tel: +44 (0)114 267 3300
.

Participant No.

Your Results On Survey LA 21: August 2023

The following pages contain information showing your results and interpretations for sample LA 23:02, distributed for Lupus Anticoagulant (LA) screening. Participants were invited to investigate using whichever methods they routinely employ for LA screening. Your results have been compared, where possible, with results from other participants using the same method or test kit. Please note, performance analysis is not applied to these data. An overall report from this exercise is also included. LA 23:02 was plasma from a donor with LA. 99.6% of centres reported their results for LA23:02 as LA positive, with 0.4% reporting LA negative. Several centres graded the level of LA positivity in this sample, however, we have now requested that all centres only report positive without applying any grading. This is reflected in the table overleaf.

A UKAS accredited proficiency testing provider No. 7873. ***Reports authorised by Ian Jennings, Programme Manager, 09.10.23 v1.0***

Survey LA21

Table 1. Overall Interpretations:

	LA23:02 LA positive
Your interpretation	**Positive (Not Graded)**
Overall interpretation	**n (%)**
Lupus screen negative	**1 (0.4%)**
Borderline/equivocal	**0 (0%)**
Lupus screen positive	**258 (99.6%)**
% respondants grading strength of results (approx)	0%
Weak Positive LA	**0**
Moderate Positive LA	**0**
Strong Positive LA	**0**

16 centres did not provide an interpretation for sample LA23:02

APTT..not performed

A total of 336 APTT results were returned for this exercise, including centres returning results for 2 different reagents. Table 2 below shows your results in comparison to other centres using your reagent, and the overall median APTT ratio for each sample.
Reagent used:

Table 2: APTT breakdowns

	LA23:02 LA positive		
	APTT	**1:1 t/n**	**4:1 t/n**
Your Result (secs)	-	-	-
Your Result (ratio)	**-**	**-**	**-**
Users (n)	-	-	-
Reagent Median ratio	**-**	**-**	**-**
% deviation	-	-	-

t/n - test/normal
1:1 t/n - APTT with equal volume of test plasma and normal plasma
4:1 t/n - APTT with 1 part normal plasma to 4 parts test plasma

* - if a ratio has been reported, this is stated here. If not, where possible a ratio has been calculated from values reported in seconds, divided by the midpoint of the stated normal range.

Survey LA21

DRVVT

A total of 263 centres returned DRVVT results for this exercise. Table 3 below shows your results in comparison to other users of your method.

Method/Kit used:

Table 3: DRVVT results sample **LA23:02 LA positive**

	DRVVT Test		DRVVT Confirm		Test/confirm	Normalised Test/confirm	% correction of ratio	% correction of secs
	(secs)	(ratio)	(secs)	(ratio)	(ratio)	(ratio)		
Your Result	**95.4**	**2.68**	**38.6**	**1.22**	**-**	**2.20**	**-**	**-**
Users (n)	63	54	62	57	45	18	13	0
Median	**91.7**	**2.43**	**38.5**	**1.10**	**2.28**	**2.26**	**55**	**-**
% deviation	4	10.29	0.3	10.91	-	-2.65	-	-

*-if a ratio has been reported for DRVVT or confirm/concentratedphospholipid results, this is stated here. If not, where possible a ratio has been calculated from values reported in seconds. For all other algorithims, results are only reported if calculated by the participant

Silica Clotting Time

A total of 87 centres returned Silica clotting time (SCT) for this exercise. Table 4 below shows your results in comparison to other users of your method.

Method/Kit used:

Table 4: SCT results sample **LA23:02 LA positive**

	SCT Test		SCT Confirm		Test/confirm	Normalised Test/confirm
	(secs)	(ratio)	(secs)	(ratio)	(ratio)	(ratio)
Your Result	**262.2**	**4.13**	**125.2**	**2.13**	**-**	**1.94**
Users (n)	8	8	8	8	5	5
Median	**90.1**	**2.46**	**46.1**	**1.55**	**1.52**	**1.52**
% deviation	191	67.89	171.6	37.42	-	27.63

*-if a ratio has been reported for SCT or confirm/concentratedphospholipid results, this is stated here. If not, where possible a ratio has been calculated from values reported in seconds. For all other algorithims, results are only reported if calculated by the participant

Anticardiolipin Assay

A total of 271 centres returned Anticardiolipin assay for this exercise. Table 5 below shows your results in comparison to other users of your method.

Table 5: Anticardiolipin results sample LA23:02

Assay	Kit	Your Result	Users (n)	Median	% Dev
ACLA IgG		**66**	25	**87**	-24.14
ACLA IgM		**1.8**	22	**2.5**	-28
B2GP1 IgG		**105**	20	**121**	-13.22
B2GP1 IgM		**0.6**	17	**1.1**	-45.45
-	-	**-**	-	**-**	-

Survey LA21

KCT..not performed

A total of 2 centres returned KCT results for this exercise. Table 6 below shows your results in comparison to other centres using of your method.

Method used:

Table 6: KCT results

	LA23:02 LA positive		
	KCT test Sec	KCT test ratio*	KCT 1:4 mix ratio*
Your Result	**-**	**-**	**-**
Users (n)	-	-	-
Median	**-**	**-**	**-**
% deviation	-	-	-

KCT 1:4 mix ratio - KCT with 1 part test plasma and 4 parts normal plasma.

* - if a ratio has been reported by participants, this is stated here. If not, where possible a ratio has been calculated from the values reported by participants in seconds.

Thromboplastin dilution test..not performed

Summary of TDT data

LA23:02

1 centre reported a TDT/dPT, using IL Recombiplastin 2G. dPT (1:1) >9.99

Miscellaneous Investigations..not performed

Summary of Miscellaneous Investigations

LA23:02

7 centres reported a PT, 4 reporting normal results. 6 centres reported TT results, 5 reporting normal. 2 centres reported fibrinogen results (all normal). 1 reported a reptilase time.

3 centres reported a dilute APTT result, and 11 reported a ratio of LA insensitive to LA sensitive APTT reagent results (all those providing an interpretion reported positive). One centre described this as a Lupus Anticoagulant APTT Ratio (LAAR). 1 reported use of the Staclot LA assay. 1 centre used a 3rd APTT reagent. 1 reported a factor VIII assay (68.2%), 1 an anti-Xa assay (0.05u/ml). Miscellaenous assay returns for some centres required rewriting to fit the space limitations on the report.